These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 8324616

  • 1. GnRH analogues for contraception.
    Fraser HM.
    Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
    [Abstract] [Full Text] [Related]

  • 2. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 3. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 4. Developments in the control of testicular function.
    Swerdloff RS, Wang C, Bhasin S.
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
    Bouchard P, Wolf JP, Hajri S.
    Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel peptides in ovarian follicular fluid: implications for contraceptive development.
    Schwartz NB.
    Res Front Fertil Regul; 1982 Sep; 2(2):1-11. PubMed ID: 12179632
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Yen SS.
    Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
    Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL.
    J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
    [Abstract] [Full Text] [Related]

  • 20. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S, Charbonnel B, Massai MR, Marraoui J, Spitz I, Bouchard P.
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.